E-Book

E-Book 2nd Congress

  • Management and prevention of red cell alloimmunization in pregnancy
  • Abolfazl Miri,1,* Kiana Tavakoli,2 Motahareh Sadeghi,3 Fatemeh Malekzadeh,4 Younes Sadeghi Bojd,5 Mobina Nakhaei,6
    1. Student Research Committee, Department of Medical Laboratory Sciences, Zahedan University of Medical Sciences, Zahedan, Iran
    2. Student Research Committee, Department of Medical Laboratory Sciences, Zahedan University of Medical Sciences, Zahedan, Iran
    3. Student Research Committee, Department of Medical Laboratory Sciences, Zahedan University of Medical Sciences, Zahedan, Iran
    4. Student Research Committee, Department of Medical Laboratory Sciences, Zahedan University of Medical Sciences, Zahedan, Iran
    5. Department of laboratory sciences,School of Allied Medicine,Zahedan University of Medical Sciences,Zahedan,Iran
    6. Student Research Committee, Department of Medical laboratory sciences, Zahedan University of Medical Sciences, Zahedan, Iran


  • Introduction: If the mother is RhD negative and the fetus RhD positive, the mother may react to fetal blood cells in her circulation by developing a template for producing anti-D antibodies. Rh Immune Globulin (RhIg) can be given to RhD-negative women to prevent sensitization and hence prevent HDN. The objective of this systematic review management and prevention of the red cell in all immunized pregnancy.
  • Methods: We searched four computerized databases for studies that described the treatment or prevention of alloimmunization in pregnancy (PUBMED, MEDLINE, EMBASE, Cochrane Database of Systematic Reviews) from 2017 to July 2021.
  • Results: Although the data suggested when women receive anti-D at 28- and 34-weeks’ gestation, a reduced incidence of immunization during pregnancy (0R O.44, 95% CI 0.18-1.12), after the birth of a Rhesus-positive infant (OR 0.44, 95% CI 0.18-1.12), and within 12 months after the birth of a Rhesus positive infant (OR 0.22 95% CI 0.05-0.88), none of these differences were statistically significant. In the trial, which used the larger dose of anti-D (100ug; 500IU), there was a clear reduction in the incidence of immunization at 2-12 months following birth in women who had received Anti-D at 28 and 34 weeks (OR 0.22 95% CI 0.05-0.88). No differences were observed in the incidence of neonatal jaundice.
  • Conclusion: Anti-D, given within 72 hours after childbirth, reduces the risk of RhD alloimmunization in Rhesus-negative women who have given birth to a Rhesus-positive infant. However, the evidence on the optimal dose is limited.
  • Keywords: Rh Blood-Group System, Neonatal Alloimmune, pregnancy